Indivior reported -144M in Equity Capital and Reserves for its fiscal semester ending in March of 2026.





Equity Capital And Reserves Change Date
AstraZeneca USD 50.3B 2.96B Jun/2026
Cassava Sciences USD 68.14M 6.26M Mar/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Roche Holding CHF 32.69B 1.11B Jun/2026
West Pharmaceutical Services USD 2.99B 200K Jun/2026